Chronic Kidney Disease As a Potential Indication for Renal Denervation by Margreet F. Sanders & Peter J. Blankestijn
REVIEW
published: 08 June 2016
doi: 10.3389/fphys.2016.00220
Frontiers in Physiology | www.frontiersin.org 1 June 2016 | Volume 7 | Article 220
Edited by:
Kyungjoon Lim,
Baker IDI Heart and Diabetes Institute,
Australia
Reviewed by:
Jacqueline Kathleen Phillips,
Macquarie University, Australia
Yusuke Sata,
Baker IDI Heart and Diabetes Institute,
Australia
*Correspondence:
Peter J. Blankestijn
p.j.blankestijn@umcutrecht.nl
Specialty section:
This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology
Received: 11 November 2015
Accepted: 26 May 2016
Published: 08 June 2016
Citation:
Sanders MF and Blankestijn PJ (2016)
Chronic Kidney Disease As a Potential
Indication for Renal Denervation.
Front. Physiol. 7:220.
doi: 10.3389/fphys.2016.00220
Chronic Kidney Disease As a
Potential Indication for Renal
Denervation
Margreet F. Sanders and Peter J. Blankestijn *
Department of Nephrology and Hypertension, University Medical Centre Utrecht, Utrecht, Netherlands
Renal denervation is being used as a blood pressure lowering therapy for patients with
apparent treatment resistant hypertension. However, this population does not represent
a distinct disease condition in which benefit is predictable. In fact, the wide range
in effectiveness of renal denervation could be a consequence of this heterogeneous
pathogenesis of hypertension. Since renal denervation aims at disrupting sympathetic
nerves surrounding the renal arteries, it seems obvious to focus on patients with
increased afferent and/or efferent renal sympathetic nerve activity. In this review will be
argued, from both a pathophysiological and a clinical point of view, that chronic kidney
disease is particularly suited to renal denervation.
Keywords: renal denervation, chronic kidney disease, hypertension, sympathetic nervous system, renin-
angiotensin-aldosterone-system
INTRODUCTION
Renal denervation (RDN) is an invasive procedure in which a catheter is percutaneously introduced
into the renal arteries. By applying radiofrequency energy against the blood vessel wall, nerve fibers
surrounding the artery are damaged (Steigerwald et al., 2012). Sympathetic nerves fibers are the
specific target (Schlaich et al., 2009a). The procedure is non-selective, meaning in this context that
both afferent and efferent pathways are affected (Booth et al., 2015). So far, RDN is mostly applied
to apparent treatment resistant hypertensive patients (aTRH). Resistant means uncontrolled blood
pressure despite the use of≥3 optimally dosed blood pressure lowering drugs, including a diuretic,
or treatment with≥4 blood pressure lowering drugs (Rossignol et al., 2015). When applying RDN,
the assumption is that renal sympathetic nerves are too active and that this activity is the main
contributor to hypertension in these patients. This assumption might actually not be true for all
hypertensive patients. RDN studies so far have all shown an exceptionally large range in blood
pressure lowering effect (Bhatt et al., 2014; Azizi et al., 2015). Especially the first sham-controlled
trial, Symplicity HTN-3, did not show superiority of RDN to a sham procedure in lowering blood
pressure and raised many questions (Bhatt et al., 2014). Secondary analyses and subsequent studies
indicated that possibly in many cases the denervation was incomplete, because of too few or
inappropriate location of ablation points (Kandzari et al., 2015). There was also uncertainty about
medication change during the studies. These and possibly other unidentified factors may have
substantially affected the outcome of the study. Furthermore, there is increasing debate on which
patient categories should be offered this therapy. The major disadvantage of the aTRH patient as
candidate for RDN is that this type of patients does not represent a distinct disease condition. In
fact the opposite is true, with RDN being applied to very mixed groups of patients (Verloop et al.,
2013; Persu et al., 2014a). So, failure to prove RDN efficacy might partly be explained by incomplete
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nerve ablation and partly by inaccurate patient selection.
Therefore, we believe that RDN research should be focused
on more distinct patient groups, in whom it is theoretically
likely that they suffer from (highly) activated renal sympathetic
nerves. In this review it will be argued that hypertensive
patients with chronic kidney disease (CKD) could be such a
target population, and indeed there is now evidence available
to suggest that CKD patients may benefit from RDN (Hering
et al., 2012; Kiuchi et al., 2013; Schlaich et al., 2013; Ott et al.,
2015).
RENAL DENERVATION IN PATIENTS WITH
CKD AND HYPERTENSION
RDN is performed from within the renal arteries and aims
at disrupting renal sympathetic nerve traffic. It is well known
that (renal) sympathetic nerve activity is increased in CKD
patients and that the prognostic consequences of this may be
significant (Zoccali et al., 2002). Therefore it seems logical to
investigate CKD as a specific indication for RDN. The arguments
to support this will be discussed from both a clinical and a
pathophysiological stance.
Unmet Need in CKD from a Clinical Point
of View
Hypertension is highly prevalent in CKD patients and is both
a cause and a consequence of chronic kidney failure (defined
as kidney damage and/or impaired kidney function for at
least 3 months, with health implications) (Rossignol et al.,
2015). More than 20% of individuals with CKD suffer from
hypertension, increasing to over 80% in patients with stage
4 kidney disease (Mahmoodi et al., 2012). In a recent meta-
analysis the additional mortality and end-stage kidney disease
(ESKD) risk of hypertension in CKD patients was investigated.
They showed that the risk of (cardiovascular) mortality and
ESKD was not much different in hypertensive CKD patients
compared to CKD patients without hypertension (Mahmoodi
et al., 2012). The hazard ratio remained the same after a
sensitivity analysis in which the definition “hypertension” also
included blood pressure lowering drug use. This suggests that
the risk of cardiovascular mortality and ESKD is partially blood
pressure independent. Several other studies have shown that
in CKD patients with inadequately controlled blood pressure,
outcome is particularly poor (de Nicola et al., 2011; Daugherty
et al., 2012; de Beus et al., 2015; Thomas et al., 2016). Prevalence
of aTRH in hypertensive CKD patients ranges from 23 to 42%,
increasing with severity of kidney disease (Muntner et al., 2010;
Mahmoodi et al., 2012; Tanner et al., 2013; de Beus et al.,
2015). Such patients have a poorer prognosis despite extensive
pharmacological treatment. Both the degree of albuminuria and
reduction of GFR are associated with outcome and with the
presence of aTRH (Sarnak et al., 2003; Foster et al., 2007; Tanner
et al., 2013). Although often accompanied by comorbidities, such
as diabetes and hypertension, CKD as such is an independent
risk factor for cardiovascular disease and mortality (Mahmoodi
et al., 2012; Matsushita et al., 2015). Close interaction between
the heart and kidney is often called cardio-renal syndrome.
Secondary cardiac involvement in CKD has been defined as
chronic renocardiac syndrome type 4 (Ronco et al., 2008).
Across all stages of reduced GFR, primary CKD can lead to
decreased cardiac function, cardiac hypertrophy and to higher
risk of cardiovascular events (Ronco et al., 2008; Hatamizadeh
et al., 2013). Furthermore, as is addressed in the next paragraph,
increased sympathetic nerve activity is also an independent
predictor of morbidity and mortality in patients with ESKD
(Zoccali et al., 2002). It seems clear that given the fact that
aTRH is so common in CKD and related to poor outcome,
there is a clinically relevant yet unmet need to improve the
quality of treatment. This “call for action” was emphasized in
a recent review (Rossignol et al., 2015). In the next section will
be discussed how RDN might be an effective treatment for these
high risk patients.
Rationale from a Pathophysiological Point
of View
The prominent role of the sympathetic nervous system (SNS)
in CKD and hypertension has extensively been discussed by us
and others (Schlaich et al., 2009b; Vink and Blankestijn, 2012;
Grassi et al., 2015; Sata and Schlaich, 2016). We will briefly
summarize this. Inmany studies sympathetic activity is measured
by quantifyingmuscle sympathetic nerve activity (MSNA), which
is the centrally originated sympathetic outflow toward the
resistance vasculature. Organ specific sympathetic activity can
be assessed by regional spillover techniques, including that to
the kidneys (Grassi et al., 2015). Regardless of the underlying
cause of disease, sympathetic nerve activity is increased in most
patients with CKD (Blankestijn, 2004). Even in early stages of
the disease, this overactivity is already present. It increases in
parallel with the progression of kidney function impairment
(Grassi et al., 2011). Importantly, markers of sympathetic activity,
such as MSNA, noradrenaline and neuropeptide Y are on average
elevated in CKD patients, but show considerable variation
(Zoccali et al., 2002, 2003; Blankestijn, 2004). In 1992, Converse
et al. compared sympathetic activity of haemodialysis patients
with normal subjects and also with haemodialysis patients
who underwent bilateral nephrectomy (Converse et al., 1992).
MSNA appeared to be increased in haemodialysis patients
and hypertensive patients with chronic kidney failure who are
not yet on dialysis (Converse et al., 1992; Ligtenberg et al.,
1999; Klein et al., 2003; Neumann et al., 2007). After bilateral
nephrectomy in haemodialysis patients, MSNA decreased to
normal levels, whereas no change in MSNA was observed after
unilateral donor nephrectomy (Converse et al., 1992; Klein
et al., 2003). So, removing a healthy kidney does not affect
MSNA (despite GFR reduction), whereas removing diseased
kidneys will lower MSNA. This finding suggests that the
sympathetic overactivity is not explained by a reduced kidney
function per se or by the uremic state, but that it is generated
within the diseased kidneys (Hausberg et al., 2002; Klein
et al., 2003). There is much evidence that kidney ischemia is
the primary cause for sympathetic nerve activation. Inducing
ischemia by acute renal artery stenosis in conscious rats results
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in both neurogenic and humoral responses (activation of the
renin-angiotensin-aldosterone system, RAAS) and consequently
in hypertension (Navar et al., 1998). In humans, MSNA was
significantly reduced after angioplasty of renal artery stenosis
(Miyajima et al., 1991). In hypertensive patients with polycystic
kidney disease, a condition characterized by regional hypoxia,
sympathetic nerve activity is increased, although kidney function
was not impaired (Klein et al., 2001; Bernhardt et al., 2007).
Sympathetic nerve stimulation from the brain to the kidney
and vice versa seems to be a vicious cycle: interruption of
the renal afferent nerves by dorsal rhizotomy (a definitive
method for afferent RDN) prevented hypertension, secretion
of noradrenaline from the posterior hypothalamic nuclei and
prevented the progression of renal disease in rats (Campese
et al., 1995). As earlier explained, catheter-based RDN is non-
selective and thus targets both afferent and efferent renal
sympathetic pathways (Booth et al., 2015; Sata and Schlaich,
2016).
INTERACTION BETWEEN SYMPATHETIC
NERVES AND RENIN-ANGIOTENSIN-
ALDOSTERONE-SYSTEM
As has long been recognized, the SNS and the RAAS are often
simultaneously upregulated. For instance, after angioplasty in
patients with renal artery stenosis, activity of both SNS and
RAAS decrease. This is also illustrated by Klein et al: in patients
with chronic kidney failure, both MSNA and the level of plasma
renin activity were higher compared to controls and reacted
parallel to each other along with changes in extracellular volume
status (Klein et al., 2003). There is strong evidence that these
systems also interact in their contribution to hypertension and
progression of kidney failure. In the renal ablation rat model
(renal mass reduction), kidney function can be preserved by ACE
inhibition (ACEi), angiotensin-II receptor blocker (ARB), or by
alpha- or beta blockade (Joles and Koomans, 2004). Treating
hypertensive, chronic kidney failure patients with ACEi or ARB,
lowers blood pressure and MSNA (Ligtenberg et al., 1999;
Klein et al., 2003). Furthermore, intravenous administration
of angiotensin-II to healthy individuals results in an increase
in MSNA, independently of baroreceptor reflexes (Matsukawa
et al., 1991). It is thought that the stimulated RAAS (by
angiotensin-II) leads to hypertension in several different ways:
directly by arteriolar constriction, via baroreceptor reflexes,
via sympathetic nerve terminals and ganglia, via the central
nervous system and via the kidneys by influencing salt and
water handling (Reid, 1992). The effects on the SNS seem to
play a significant role: RDN in rats attenuates hypertension
that is caused by chronic angiotensin-II infusion (Hendel
and Collister, 2006). Similar, Eriguchi et al. found that in
rats with cardiorenal syndrome, induced by chronic L-NAME
administration (causing NO depletion), bilateral RDN decreased
local RAAS activity (Eriguchi et al., 2015). It is clear that
interaction between the two systems is bidirectional. This could
be due to bidirectional cause-effect relations, a common origin,
or both.
LOWERING SYMPATHETIC NERVE
ACTIVITY
As stated earlier, MSNA represents the sympathetic outflow
toward the resistance vasculature. It is thought to be involved
in the pathogenesis of hypertension. Indeed, in an earlier study
we found a positive relationship between MSNA levels and blood
pressure (Siddiqi et al., 2009). In order to appreciate the effect
of RDN on the SNS, it is important to know to what extent
the currently often used drugs lower sympathetic activity in
disease conditions characterized by sympathetic hyperactivity.
It seems logical to aim at normalization. Insufficient reduction,
i.e. not normalization, could suggest an unmet need. Basically,
there are at least two types of sympathetic activity quantified
by MSNA: a control level and an overactivated state. The
control activity is generated by the central nervous system,
influenced by baroreceptors and is present in every individual,
even in bilaterally nephrectomized subjects (Blankestijn and
Ritz, 2011). As explained, overactivity can be generated in
the diseased kidney. In patients with sympathetic overactivity,
the aim of therapy is to reduce this activity, back to levels
comparable to normal subjects. We were the first to show that
an ACE-inhibitor reduces MSNA in CKD patients (Ligtenberg
et al., 1999; Neumann et al., 2007). However, MSNA did not
normalize during treatment with normal dosages of ACEi or
ARB (Figure 1) (Klein et al., 2003). Insufficient suppression has
been confirmed in multiple clinical trials studying hypertensive
CKD patients (Neumann et al., 2004, 2007; Siddiqi et al., 2011).
When moxonidine (a centrally acting sympatholytic agent)
was added to the treatment, both blood pressure and MSNA
further decreased (Neumann et al., 2004). Monotherapy of
certain oral beta-blocking agents leads to a reduction in MSNA
in hypertensive and in chronic heart failure patients (Wallin
et al., 1984; de Matos et al., 2004). However, like the MSNA
FIGURE 1 | Schematic representation of sympathetic nerve activity in
CKD patients and normal subjects. The blue line represents muscle
sympathetic nerve activity (MSNA) in healthy subjects, the red line represents
MSNA in untreated CKD patients and the green line represents MSNA in CKD
patients, when treated chronically with a RAAS-inhibitor (Ligtenberg et al.,
1999; Klein et al., 2003; Neumann et al., 2004, 2007; Siddiqi et al., 2011).
Sympathetic activity increases with age, irrespective of treatment. The figure
shows that chronic treatment with RAAS-inhibitors does not result in full
normalization of MSNA. This indicates the need for additional sympatholytic
therapy.
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lowering effect of RAAS inhibitors, sympathetic activity does
not reach control levels: MSNA can be further decreased for
example by regular exercise (Fraga et al., 2007). Carvedilol (a
beta-blocker) added to standard therapy (including at least one
RAAS inhibitor) in hemodialysis patients with chronic heart
failure reduced morbidity and mortality, which could be due to
sympatholytic actions (Azevedo et al., 2001; Cice et al., 2003).
One could argue that there might be a dose-effect relation:
increasing the dosage, to double or three times the normal dosage
of RAAS inhibition or beta-blocking agents, would possibly
further reduce MSNA. There is not much known about the dose-
related sympathetic lowering effects of drugs. It is also unclear
whether MSNA can completely normalize when only targeting
the SNS, pharmacologically or otherwise. Since components of
the RAAS and SNS are often simultaneously released, it seems
reasonable to believe that a combination therapy of RAAS- and
beta-blockade is essential when both systems are expected to
be overactivated. Changes in activity of SNS after RDN, e.g.
measured by MSNA, have not been consistently shown (Hart
et al., 2013; Hering et al., 2013; Vink et al., 2014a). Evidence of
parallel activation of RAAS and SNS indicate that variables of
RAAS might also be indicative of an RDN effect, a hypothesis
that is already supported by some early results by our group
(Vink et al., 2014b). To conclude, in view of the pathophysiology,
there is rationale to target both RAAS and SNS in order to
adequately lower sympathetic overactivity. It is worth addressing
the hypothesis that the combination of RAAS inhibitors and
RDN is more effective than either intervention alone.
EFFECTS OF RDN IN CKD PATIENTS AND
IN EXPERIMENTAL STUDIES
Is there any information on the effects of RDN in CKD? In
RDN research, CKD patients were originally excluded from
participation, mainly because of lack of safety data. Data now
available seem to suggest that the procedure is safe, including
in more advanced CKD, but only few studies investigated the
effects of RDN specifically in a CKD population (Hering et al.,
2012; Kiuchi et al., 2013, 2016; Schlaich et al., 2013; Ott et al.,
2015). Longer follow-up reports describe a slight decrease in
creatinine clearance, which could have many explanations, for
instance, change in medication use or natural progression due to
existing comorbidities (Krum et al., 2014; Tsioufis et al., 2015).
In the CKD population, available studies showed a significant
blood pressure reduction up to 2 years after the procedure,
although most studies were limited by a small sample size, lack
of control group and the uncertainty of medication adherence
(Hering et al., 2012; Kiuchi et al., 2013; Schlaich et al., 2013;
Ott et al., 2015; Kiuchi et al., 2016). No worsening of kidney
function was reported. In fact, in some studies the opposite
was found: Ott and colleagues observed beneficial effects on
kidney function. In this pilot study in CKD patients with
hypertension, decline of creatinine clearance slowed down after
RDN (Ott et al., 2015). These potentially beneficial effects were
also demonstrated in experimental studies. For example, in the
study by Eriguchi et al. it became clear that both hydralazine
(a direct vasodilating agent) and bilateral RDN lowered the
L-NAME induced hypertension. However, the denervated rats
showed protective effects, associated with local RAAS inhibition,
that were blood pressure independent (Eriguchi et al., 2015).
Interestingly, the results of this experimental study might be in
line with the previously cited meta-analysis, showing that the
morbidity and mortality risks in CKD patients are partially blood
pressure independent (Siddiqi et al., 2011). So these early studies
indicate that RDN in (advanced) CKD is safe. Based on limited
evidence, RDNmight even be renoprotective, an effect that could
be blood pressure-independent.
PERSPECTIVES
There are several aspects of the topic of this review that have
not yet been touched upon here and seem appropriate to briefly
discuss. First of all, we need to focus on how to improve
the selection for RDN within the CKD population. Clinical
studies investigating baseline differences between responders and
non-responders to RDN did not consistently produce useful
pretreatment predictors (Kaiser et al., 2014; Persu et al., 2014b;
Vink et al., 2014b; Kandzari et al., 2015). In a recent review,
potential strategies for selecting CKD patients for RDN are
described in more detail (de Beus et al., 2014). These strategies
are more based on the pathophysiology and could therefore
be a potential focus of further research. Another important
issue is the recent knowledge of the ability of renal sympathetic
nerves to re-innervate after RDN. Although long-term follow-
up studies, up to three years after RDN, showed a persistent
blood pressure lowering effect, preclinical research demonstrated
both functionally and anatomically that re-innervation occurred
within 12 months after the procedure (Mulder et al., 2013; Esler
et al., 2014; Krum et al., 2014; Booth et al., 2015). It should
be investigated whether this is likely to happen in humans
as well. Despite of the uncertainties of the procedure, the
concept of a single intervention with prolonged effect is very
attractive and most likely cost effective, especially when the
price of RDN devices decreases. A so far unexplored collateral
idea is the potential environmental benefit of RDN. There is
emerging awareness that metabolites of pharmaceutical drugs
inevitably pollute the environment (Valcarcel et al., 2013). The
consequences are poorly understood but potentially disastrous
(Cok et al., 2011). RDN as a one-time non-pharmaceutical
treatment may be more environmentally friendly. Although
the rationale behind RDN in CKD patients is strong, there is
reason to be cautious. As the use of contrast imaging is part of
the intervention, there has been some concern about contrast
induced nephropathy in CKD patients. Most nephrologists
believe that this complication is rare provided that the patient
is sufficiently hydrated. It is important to realize that RDN is
an elective procedure. There is sufficient time to adequately
prepare the patient for the procedure and the risk seemsminimal.
There is concern on possible detrimental effects of the procedure
on renal artery anatomy. There are some reports on renal
artery abnormalities, such as stenosis, observed during follow-up
(Templin et al., 2013; Persu et al., 2014c). Most of these studies
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lack a control group, so it is uncertain whether the stenosis was
indeed caused by the intervention or a feature of the natural
disease course in these high risk patients.
SUMMARY AND CONCLUSIONS
We are only at the beginning of correctly positioning RDN in
the field. Up to now, RDN is mainly applied to patients with
apparent TRH. It is now clear that this non-specific indication
is not supported by knowledge on the pathophysiology of a
specific condition. Nephrologists and hypertension specialists
tend to think that true TRH is a very rare condition. In fact,
aTRH seems to be a very heterogeneous population, including
non-adherence, white coat hypertension, insufficiently dosed
patients, high salt intake and undiagnosed secondary forms.
Admittedly, aTRH is rather common, and should perhaps be
redefined as “poorly controlled blood pressure for whatever
reason.” Therefore, we need to change our way of thinking
and use a more logical, possibly blood-pressure independent,
approach for patient selection, i.e., based on the knowledge
of the clinic and the pathophysiology. In CKD patients there
is a clear unmet need, because aTRH is so often present,
persistent and associated with poor prognosis. Furthermore,
there is rather convincing evidence that the kidneys are involved
in the pathogenesis and that the renal sympathetic nerves play
a role. The bottom line is: in which patients will the addition
of sympatholytic therapy such as RDN to existing standard
therapy, that in most cases includes a RAAS inhibitor, reduce
sympathetic activity. CKD is one of the disease conditions
in which there is already some evidence that the addition
of sympatholytic therapy to RAAS inhibition may improve
prognosis. Therefore, it seems appealing to focus on this disease
condition.
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